BIOMAT Database Logo BIOMAT Database Logo

[Clinical aspects and therapy of diabetic coma]. 1981

A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007545 Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. Isoprenaline,Isopropylarterenol,4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol,Euspiran,Isadrin,Isadrine,Isopropyl Noradrenaline,Isopropylnoradrenaline,Isopropylnorepinephrine,Isoproterenol Hydrochloride,Isoproterenol Sulfate,Isuprel,Izadrin,Norisodrine,Novodrin,Hydrochloride, Isoproterenol,Noradrenaline, Isopropyl,Sulfate, Isoproterenol
D003926 Diabetic Coma A state of unconsciousness as a complication of diabetes mellitus. It occurs in cases of extreme HYPERGLYCEMIA or extreme HYPOGLYCEMIA as a complication of INSULIN therapy. Coma, Diabetic,Comas, Diabetic,Diabetic Comas
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004573 Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed) Electrolyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001639 Bicarbonates Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity. Bicarbonate,Bicarbonate Ions,Hydrogen Carbonates,Bicarbonate Ion,Carbonic Acid Ions,Hydrogen Carbonate,Carbonate, Hydrogen,Carbonates, Hydrogen,Ion, Bicarbonate,Ions, Bicarbonate,Ions, Carbonic Acid
D001645 Biguanides Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES. Biguanide
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D014325 Tromethamine An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424) Tris Buffer,Trisamine,Trometamol,Tri(hydroxymethyl)aminomethane,Tris(hydroxymethyl)aminomethane,Tris-Magnesium(II)-Potassium Chloride Buffer,Tris-Mg(II)-KCl Buffer,Trizma

Related Publications

A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Diabetic keto-acidosis and diabetic coma (pathogenesis, clinical aspects and therapy)].
October 1961, Archivio per le scienze mediche,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
Clinical aspects of diabetic coma.
December 1955, The Journal of the Indiana State Medical Association,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Diabetic acidosis and coma. (Clinical aspects)].
April 1960, El Dia medico,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Clinical aspects, therapy and comments on 30 cases of diabetic coma].
March 1957, Algerie medicale,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[New information on clinical aspects and therapy of ketoacidosis and diabetic coma].
October 1981, Minerva medica,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Physiopathological, clinical and therapeutic aspects of diabetic coma].
August 1950, Arquivos de clinica,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Clinical and metabolic aspects of the diabetic coma].
May 1956, Il Progresso medico,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Diabetic acidosis and coma; clinical and therapeutic aspects].
December 1954, La Semana medica,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[New indications on the clinical aspects and therapy of ketoacidosis and diabetic coma].
January 1982, Minerva dietologica e gastroenterologica,
A V Greco, and G Ghirlanda, and L Altomonte, and R Manna, and L Ucciolo, and S Caputo, and A Bertoli
[Diabetic coma--clinical aspect and therapy].
November 1962, Zeitschrift fur arztliche Fortbildung,
Copied contents to your clipboard!